The Medanta Institute of Liver Transplantation and Regenerative Medicine recently organised the 4th International Liver Symposium (ILS) where healthcare experts shared their viewpoint touching various aspect of liver diseases.
The event organised at Leela Ambience, Gurugram saw participation from experts from across the world. The world’s leading experts and academicians deliberated on Hepatology, Liver Surgery and Transplantation at three-day symposium which was based on the theme of “Debates in Liver Diseases and Transplantation“.
Liver cancer is the second largest cancer killer in India. 30 per cent of the Indian adult population has fatty liver. Cutting-edge treatment options and surgeries specific to these issues were presented in the symposium.
Other than lifestyle changes, renowned liver experts discussed the encouraging preliminary results with a new class of drugs – the FXR agonists – that can now reverse fatty liver. Results with new drug Lenvatinib for advanced liver cancer were also presented.
Dr A S Soin, Chairman, Medanta Institute of Liver Transplantation and Regenerative Medicine talked about Medanta’s globally acknowledged protocol, which now enables successful cure of advanced stage 4 liver cancer by combining cyberknife and TARE, followed by transplant. He also spoke about the role of machine learning algorithms and artificial intelligence in donor–recipient matching, and outcome after liver transplantation.
“The International Liver Symposium is a convergence of the leading minds, techniques, and innovations for Gastroenterologists, Hepatologists, Liver Surgeons, Anaesthetists, Intensivists, Paediatricians, Interventional Radiologists and Researchers, globally. The incidence of liver disease has risen and liver medicine and surgery have seen phenomenal rise over the last decade.
At the Medanta Liver Transplant Institute, we run the world’s second largest living donor liver transplant program, performing more than 250 transplants annually. Our team has an experience of almost 2800 liver transplants. ILS reflects our commitment to the currency of knowledge and harnessing it to deliver the best globally benchmarked treatments,” Soin said.
The group of experts additionally brainstormed about alternative approaches to managing and treating Hepatitis, Non-alcoholic Fatty Liver Disease (NAFLD), Acute-on-chronic Liver Failure (ACLF), Alcoholic Liver Disease, Hepatocellular carcinoma (HCC), Hepatic Surgery and Critical Care in adults and children.